Artelo Biosciences (ARTL) announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock and/or pre-funded warrants in the offering are to be offered by the company. R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo does not envision need to internally fund Phase 3 trial of ART27.13
- Artelo Biosciences announces interim Phase 2 CAReS results
- Artelo Biosciences Approves Common Stock Increase
- Artelo Biosciences announces data on food effect evaluation with ART26.12
- Artelo Biosciences Ends Securities Purchase Agreement